Thu, Mar 28, 2024 | UPDATED 12:48 UTC
Sep 20, 2022
New Delhi, Sept 20 (ANI): Researchers involved in a new multi-site international phase III study led by Northwestern Medicine found that a new drug was highly effective in reducing the signs and symptoms of moderate-to-severe Eczema. This is the first study to treat moderate-to-severe Eczema in infants and children 6 months to 5 years of age with a biologic drug (monoclonal antibody) instead of immune-suppressing medications. More than half the children experienced at least a 75 per cent reduction in Eczema symptoms, highly significant reductions in itching, and improved sleep after a 16-week course of dupilumab, a drug that targets a crucial immunological system in allergens. This is the first massive, random, placebo-controlled trial of a monoclonal antibody for any skin condition, including Eczema, in kids as young as six months. The study, which covered 31 locations across Europe and North America, will be released in The Lancet on September 15.
Feb 11, 2024
Oct 13, 2023
Sep 12, 2023
Sep 04, 2023
May 24, 2023
May 17, 2023
May 11, 2023
May 06, 2023
Apr 13, 2023
Feb 15, 2023
Dec 18, 2022
Nov 01, 2022
Oct 17, 2022
Oct 02, 2022